Atrium Therapeutics, Inc. Common Stock reports a Return on Equity (ROE) of -169.35%.

What is RNA's dividend yield?

Atrium Therapeutics, Inc. Common Stock offers a dividend yield of 0.00%.

What is RNA's Quality Score?

Our AI rates RNA's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy RNA?

Our AI Timing Score for RNA is 28 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does RNA belong to?

Atrium Therapeutics, Inc. Common Stock is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Atrium Therapeutics, Inc. (RNA) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

RNA AI Analysis Summary

Our AI summary for RNA: Atrium Therapeutics, Inc. Common Stock (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -169.35%, a dividend yield of 0.00%. Its financial Quality Score stands at 23/100 — fundamentals below the market average. The AI Timing Score is 28/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

RNA

Atrium Therapeutics, Inc. Common Stock

US:NASDAQ STOCK Healthcare >> Biotechnology News 95

USD 11.54

0.21 (1.85%) Day Change

Watchlist Portfolio Compare Chart

0.01

D/E

-169.4%

ROE

-135.6%

ROA

0.00%

Div Yield

ATRIUM THERAPEUTICS, INC. COMMON STOCK
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 11.54 Price 0.21 (1.85%) Day Change	NEWS SCORE: 95

RNA, the overall quality is not good ( Quality = 23) and the timing to buy is ...(Sign In to See)...

Loading chart...

23 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...

Quality Factors

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	95
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	11.54
PBV / Sector	0.83 / 44,022.72 GREAT
Earning Per Share	-23.61

PE / Sector	N/A / 19.17
PEG or PE/Growth / Sector	N/A / 1.24
Average 1M Daily Value	1.72 M GREAT
Average 1W Daily Value	1.27 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

50%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

54%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-1,076.87 / 98.24
NPM Average (%) / Sector	-1,699.87 / -1,697.63
NPM Change Average (%) / Sector	32.43 / 5,097.97 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-135.61 / 185,260.96
ROA Average (%) / Sector	-48.80 / 36,684.70
ROA Change Average (%) / Sector	103.63 / 422,221.66 GREAT
ROE (%) / Sector	-169.35 / 243,762.23
ROE Average (%) / Sector	-60.12 / 48,758.47
ROE Change Average (%) / Sector	104.90 / 424,968.10 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 08:00:47
Symbol	RNA
Name	ATRIUM THERAPEUTICS, INC. COMMON STOCK
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	17.11 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	193.81 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 10578 Science Center Drive, San Diego, CA, United States, 92121

Phone: 619 876 0700

Website: https://atriumtherapeutics.com

Employees: 511

Sector: Healthcare >> Biotechnology

Description: Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.